This study aimed to assess the effectiveness and safety of tocilizumab use for the treatment
of active steroid-resistant Graves' orbitopathy (GO). A retrospective longitudinal study was …

Objective To demonstrate the efficacy of the anti-interleukin-6 receptor monoclonal antibody
tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy …

Graves' orbitopathy (GO) is the most common extrathyroidal manifestation of Graves'
disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO …

Background Up to 20% of patients with moderate to severe Graves' orbitopathy (GO) do not
respond to high‐dose glucocorticoids (GC). A few studies, including a randomized trial, have …

Purpose To describe pre-to post-treatment changes in clinical activity score (CAS) and
exophthalmometry in patients with Graves orbitopathy treated with tocilizumab (TCZ) …

Purpose: To assess the efficacy of Tocilizumab, a humanized monoclonal antibody against
the interleukin-6 receptor, in thyroid eye disease patients refractory to multiple intravenous …

Objectives A beneficial effect of sirolimus in Graves' orbitopathy (GO) was reported,
suggesting a possible use in clinical practice. We conducted an observational, single-centre …

The medical treatment of Graves' orbitopathy (GO) is usually reserved to moderate to severe
disease. Steroids have been widely employed and possess anti-inflammatory activity, but …

Study Objective To investigate the efficacy and safety of rituximab in patients with Graves'
orbitopathy (GO). Design Systematic review and meta‐analysis of four randomized …

Purpose The clinical utility of rituximab (RTX) in Graves' orbitopathy (GO) treatment remains
controversial since the discrepant results from 2 prospective randomized studies (Stan M et …